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Several algorithms for early prediction of poor-mobilizing patients after chemotherapy and granulocyte
colony-stimulating factor administration have been proposed. They generally deﬁne peripheral blood cut-off
levels of CD34þ cells at a ﬁxed day after starting chemotherapy, mostly with cyclophosphamide. To deﬁne an
algorithm for early addition of plerixafor regardless of the chemotherapy regimen used, we retrospectively
analyzed 280 chemomobilization attempts in 236 patients treated at our institution between 2002 and 2012.
In multivariate analysis, CD34þ absolute count and CD34þ percentage upon total leukocyte count at day 1
(deﬁned as the ﬁrst day in which leukocytes reached a value > 1  109/L) were the only factors able to predict
a total harvest  2  106 CD34þ/kg. In patients with day 1 CD34þ lower than 20/mL, the CD34þ percentage
was a more reliable predictor of stem cell harvest in the following days than CD34þ absolute count. Upon
deﬁnition of the best CD34þ cut-off value for identiﬁcation of poor-mobilizing patients, an algorithm was set
up to guide plerixafor administration. It was prospectively validated in 20 patients in 2013 with encouraging
results in terms of low incidences of both mobilization failure and plerixafor use. Large prospective trials that
deﬁne the most cost-effective strategy for just-in-time rescue plerixafor are warranted.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy followed by autologous trans-
plantation with peripheral blood stem cells (PBSCs) is a
standard treatment in patients with multiple myeloma (MM)
and relapsed/refractory lymphoma. However, the common
mobilization strategy using granulocyte colony-stimulating
factor (G-CSF) with or without chemotherapy fails to har-
vest the target CD34 þ dose of 2  106/kg in up to 40% of
patients [1,2].
Plerixafor (PLX) is a CXCR4 antagonist that inhibits he-
matopoietic stem cell binding and chemotaxis to bone
marrow stroma. Because of a complementary mechanism of
action, it synergistically acts with G-CSF in promoting stem
cell mobilization. The addition of PLX to G-CSF allowed
adequate stem cell mobilization in patients who previously
failed mobilization [3] and was superior to G-CSF alone as an
upfront mobilization strategy [4]. Because of the high cost, it
has been suggested that PLX should be limited to a selected
poor mobilizer population [5].dgments on page 722.
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14.02.002Different strategies have been proposed: (1) remobiliza-
tion with PLX in proven poor mobilizers, (2) preemptive use
in predicted poor mobilizers, and (3) administration of PLX
“on demand” during the ﬁrst mobilization attempt. The ﬁrst
strategy has the advantage of limiting PLX use to selected
patients unable to harvest adequate stem cell amounts with
G-CSF with or without chemotherapy. However, remobili-
zation itself is both resource and time consuming. On the
other hand, preemptive use of PLX [6] is safe and allows a
high success rate due to PLX capability of overcoming the
negative effect of poor mobilization predictors [7]. However,
because certain predictors of insufﬁcient CD34 þ harvest are
still lacking, some of these patients may also be able to
mobilize without PLX. Recently, Costa et al. [8] showed that
clinical premobilization characteristics should not be used to
stratify MM patients for different mobilization strategies.
Several authors investigated the feasibility of algorithms
for early recognition of poor-mobilizing patients who could
mostly beneﬁt from the addition of PLX during a ﬁrst
mobilization attempt. In patients undergoing PBSC mobili-
zation with G-CSF alone, a low CD34 þ count on day 4 [9,10]
or 5 [11,12] was almost universally considered as predictor of
harvest failure. In patients in which PBSC mobilization was
tempted with chemotherapy plus G-CSF, the identiﬁcation of
early cut-off CD34 þ values was more difﬁcult, due to higher
Transplantation.
Table 1
Patient and Mobilization Characteristics
Characteristic Retrospective
Analysis
Prospective
Analysis
No. of patients 236 20
Male/female sex 153/83 14/6
One mobilization attempt 195 20
Two mobilization attempts 38 d
Three mobilization attempts 3 d
Median age at mobilization,
yr
58 59
Mobilization attempts 280 20
Disease, no. of mobilizations
MM 110 12
Non-Hodgkin lymphoma 140 7
Hodgkin lymphoma 25 1
Lymphoblastic lymphoma 5 d
Chemotherapy regimen,
no. of mobilizations
Cyclophosphamide 178 13
3-4 g/m2 150 13
6-7 g/m2 28 d
Cytarabine-based 77 4
HD-ARAc 29 d
DHAP or DAOX 13 3
MAD 13 d
MTXþARAc 13 1
HyperCHiDAM 7 d
Other 2 d
Other chemotherapy
regimens
25 3
IGEV 8 d
Escalated BEACOPP 7 1
Other 10 2
HD-ARAc indicates high-dose cytarabine 2 g/m2 q 12 h for 4-6 days; DHAP,
dexamethasone 40 mg/d from day 1 to 4, cisplatin 100 mg/m2 on day 1,
cytarabine 2 g/m2 q 12 h onday 2; DAOX, dexamethasone 40mg/d fromday 1
to 4, oxaliplatin 130mg/m2 on day 1, cytarabine 2 g/m2 q 12 h on day 2;MAD,
mitoxantrone 8mg/m2 plus cytarabine 2 g/m2 q 12 h plus dexamethasone 4 g
q 12 h from day 1 to day 3; MTXþARAc, methotrexate 3.5 g/m2 on day 1 plus
cytarabine 2 g/m2 q 12 h on days 2-3; HyperCHiDAM,methotrexate 2 g/m2 on
day 1, hyperfractionated cyclophosphamide 300 mg/m2 plus cytarabine
2 g/m2 q 12 h from day 2 to 4; IGEV, ifosfamide 2 g/m2 plus gemcitabine
800 mg/m2 plus prednisolone 100 mg from day 1 to 4, vinorelbine 20 mg/m2
on day 1; escalated BEACOPP, doxorubicin 35mg/m2 plus cyclophosphamide
1250 mg/m2 on day 1, etoposide 200 mg/m2 from day 1 to 3, dacarbazine
100mg/m2 fromday 1 to 7, prednisone 40mg/m2 fromday1 to 14, bleomycin
10 mg/m2 plus vincristine 1,4 mg/m2 on day 8.
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chemotherapy and to differences between chemotherapy
schedules [13-16].
To deﬁne a simple algorithm to limit the use of PLX to
poor-mobilizing patients, we retrospectively analyzed the
PBSC harvest of all patients consecutively treated at our
institutionwith chemotherapy and G-CSF between 2002 and
2012. Considering that G-CSFemobilized CD34 þ reach a
peak and then decrease, whereas leukocyte counts steadily
increase over time [17], we focused on both CD34 þ absolute
count (CD34/mL) and CD34 percentage upon total leukocyte
count (CD34%) at hematological recovery, irrespective of the
chemotherapy schema.
METHODS
This retrospective analysis was approved by the Institutional Ethics Com-
mittee of Santa Croce e Carle Hospital and was registered at ClinicalTrial.gov
as NCT02023814. All mobilization attempts with chemotherapy plus G-CSF
performed between 2002 and 2012 were included. Mobilizations with G-CSF
alone and mobilizations with PLX were excluded.
After chemotherapy, patients received lenograstim or ﬁlgrastim until
completion of CD34þ harvest or failure. Peripheral blood CD34þ count, as
provided by ﬂow cytometry through a single platform method, was moni-
tored daily starting from the day of probable hematological recovery. Stem
cell collection was started when CD34þ absolute count was greater than 15
to 20/mL, as per institutional protocol.
Peripheral blood CD34% and CD34/mL at the ﬁrst day inwhich leucocytes
reached the value of 1  109/L and remained beyond this threshold over at
least 2 days (days 1 and 2) were correlated with overall CD34þ collection.
According to the deﬁnition by the Gruppo Italiano Trapianto Midollo Osseo
[2], harvest less than 2  106 CD34þ/kg was considered a failure. Moreover,
harvest less than 4  106 was considered suboptimal [18].
The primary end-point of the study was the identiﬁcation of a cut-off
level of peripheral blood CD34þ for early detection of poor mobilizers.
Correlations were evaluated with linear regression (R test) and differences
betweenmedians with Mann-Whitney test; the chi-square test was used for
categorical data analyses. A multivariate logistic regression model was used
to assess the predictive value of CD34% and CD34/mL on harvest  2  106
CD34þ/kg: because these two variables are collinear, they were separately
analyzed in a hierarchical model that also included the other variables
showing in univariate analysis a signiﬁcant impact on the outcome.
Receiver operating characteristic (ROC) curve analysis was used for
identiﬁcation of the most accurate cut-off value of percent and absolute
CD34þ values at days 1 and 2 to predict mobilization outcome. Area under
the curve (AUC) for each diagnostic test was provided with 95% conﬁdence
interval (95% CI); a test was considered useful in determining mobilization
failure if AUC was signiﬁcantly higher than .5. Differences between AUCs of
ROC curves obtained with different diagnostic tests (AUC1 e AUC2) were
provided with 95% conﬁdence intervals and evaluated with a z-test. Prob-
ability levels lower than .05 were considered statistically signiﬁcant.
An algorithm to guide the use of PLX in patients at high risk of mobili-
zation failure based on deﬁnite CD34þ percent and absolute counts on days
1 and 2 was then set up and prospectively validated in a cohort of patients
undergoing PBSC mobilization for autologous transplantation in 2013. Sta-
tistical analysis was performed with the commercially available software
NCSS-2007 (NCSS, Kaysville, UT).
RESULTS
Patient Characteristics
Between January 2002 and October 2012, 236 patients,153
men and 83 women, underwent 1 or more mobilization
procedures with chemotherapy and G-CSF at our institution.
Patients and mobilization characteristics are summarized in
Table 1. Brieﬂy, the breakdown of patients undergoing PBSC
mobilization was as follows: non-Hodgkin lymphoma, 118;
MM, 89; Hodgkin lymphoma, 24; and acute lymphoblastic
leukemia/lymphoma: 5. Median age at mobilization was
58 years (range, 17 to 72). Forty-one patients underwent at
least 2 mobilization procedures: 18 myeloma and 22 lym-
phoma patients enrolled in protocols requiring 2 chemo-
mobilization attempts (2 courses of cyclophosphamide 4 g/m2
in myeloma, 2 cytarabine-based regimens, or a course ofcyclophosphamide 6 to 7 g/m2 followed by 1 of high-dose
cytarabine in lymphoma). Of these, 2 patients with mye-
loma underwent a third mobilization attempt because of an
inadequate harvest and 1 patient with lymphoma performed
2 planned cytarabine-based cycles after cyclophosphamide,
all with adequate harvest. An additional myeloma patient
underwent a second course of cyclophosphamide due to
suboptimal harvest after the ﬁrst one. Globally, 280 mobili-
zation procedures were recorded. Chemotherapy included
cyclophosphamide alone in 178, cytarabine-based regimens
in 77, and other regimens in 25. All patients received G-CSF
with different schedules according to the chemotherapy
regimen, as per standard clinical practice.Mobilization Outcome
Median leukocyte count, CD34%, and CD34/mL at day 1
were 3.5  109/L (range, 1 to 60), .59% (range, 0 to 16.5), and
21/mL (range, 0 to 834), respectively. Globally, 34 procedures
(12%) failed, 16 (6%) were suboptimal, and 230 (82%) reached
the optimal CD34þ dose higher than 4106/kg. In successful
mobilizations, the median harvest was 12.1  106 CD34þ/kg
(range, 2.3 to 82.4).
Table 2
Multivariate Logistic Regression Models for Harvest  2  106 CD34þ/kg
Variables Regression
Coefﬁcient
Standard
Error
P
Model including CD34/mL
CD34/mL .29 .07 .00002
Age e.02 .02 .41
Subsequent vs. ﬁrst mobilization
attempt
e.32 .52 .53
Cytarabine-based regimen vs.
cyclophosphamide
.81 .57 .16
Other regimens vs.
cyclophosphamide
1.10 1.17 .34
Model including CD34%
CD34% 11.49 2.63 .00001
Age e.01 .02 .83
Subsequent vs. ﬁrst mobilization
attempt
e.40 .53 .46
Cytarabine-based regimen vs.
cyclophosphamide
.80 .57 .16
Other regimens vs.
cyclophosphamide
.98 1.18 .41
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Associated with Harvest
Total harvest showed inverse correlationwith age (Re.18,
P ¼ .003) and direct correlation with day 1 levels of both
CD34/mL (R .65, P < .00001) and CD34% (R .73, P < .00001),
with signiﬁcantly lowermedian levels of CD34/mL and CD34%
in patients who failed mobilization (1 versus 27/mL and .04
versus .77%, respectively, P < .00001). As expected, in 142
procedures (51%) with day 1 CD34þ higher than or equal to
20/mL, there was no failure and only 1 suboptimal harvest;Figure 1. ROC curves for all mobilization proceduresamong 138 procedures with day 1 CD34þ lower than 20/mL,
34 (25%) failed and 15 (11%) harvested less than 4  106
CD34þ/kg. Failure rate was 10% in 236 ﬁrst mobilization at-
tempts and 23% in 44 subsequent attempts (P ¼ .02). Among
11 patients with primary failure, 7 changed chemomobilizing
regimen and 4 had an adequate harvest at remobilization; 4
patients repeated the same regimen without success. The
risk of failure was not affected by disease (13% in lymphoma
and 11% in myeloma patients, P ¼ .64) and by previous
treatment with chelating agents or lenalidomide (15% versus
10% in untreated patients, P ¼ .21), provided that no patient
had prior autologous transplantation. There was a trend to a
signiﬁcant association with mobilization chemotherapy:
failure was 15% in patients treated with cyclophosphamide
alone, 8%with cytarabine-based regimens, and 4%with other
regimens (P ¼ .10). Interestingly, we found a higher risk of
failure in patients with lymphoma treated with cyclophos-
phamide alone (23%) compared to lymphoma patients
treated with cytarabine-based regimens (9%, P ¼ .06) and to
myeloma patients treated with cyclophosphamide alone
(11%, P ¼ .03).
In a multivariate model including age, mobilization
attempt (ﬁrst versus subsequent), and chemotherapy regimen
(cytarabine-based or other versus cyclophosphamide), CD34%
and CD34/mL were the only factors to maintain a signiﬁcant
correlationwithmobilization outcome (Table 2). These results
were conﬁrmed in a subgroup analysis of 140 non-Hodgkin
lymphoma mobilizations, in which CD34þ absolute and
percent count showed a regression coefﬁcient of .38 (P¼ .002)
and 10.4 (P ¼ .001), respectively; in the model with CD34/mL
but not in that with CD34%, cytarabine-based regimens also(A) and for 236 ﬁrst mobilization attempts (B).
Table 3
CD34% Sensitivity, Speciﬁcity, Positive Predictive Value, and Negative Pre-
dictive Value for Optimal Mobilization in Patients with Peripheral Blood
CD34þ Lower Than 20/mL at Days 1 and 2
Cut-Off
Value
Sensitivity Speciﬁcity Positive
Predictive
Value
Negative
Predictive
Value
Day 1 Day 2 Day 1 Day 2 Day 1 Day 2 Day 1 Day 2
.01 1.00 1.00 .04 .05 .65 .40 1.00 1.00
.02 .98 1.00 .20 .20 .69 .44 .83 1.00
.03 .96 .96 .31 .33 .71 .47 .79 .93
.04 .93 .92 .41 .38 .74 .48 .77 .88
.05 .91 .92 .45 .45 .75 .51 .73 .90
.06 .90 .84 .55 .53 .78 .53 .75 .84
.07 .87 .80 .65 .55 .82 .53 .73 .81
.08 .82 .80 .65 .63 .81 .57 .67 .83
.09 .81 .80 .67 .68 .82 .61 .66 .84
.10 .81 .76 .71 .70 .84 .61 .67 .82
.20 .65 .36 .82 .93 .87 .75 .56 .70
.30 .53 .08 .98 1.00 .98 1.00 .53 .63
.40 .42 .04 .98 1.00 .97 1.00 .48 .63
.50 .33 .04 1.00 1.00 1.00 1.00 .45 .63
.60 .28 .00 1.00 1.00 1.00 .00 .43 .62
.70 .24 .00 1.00 1.00 1.00 .00 .42 .62
.80 .18 .00 1.00 1.00 1.00 .00 .40 .62
.90 .15 .00 1.00 1.00 1.00 .00 .39 .62
1.00 .11 .00 1.00 1.00 1.00 .00 .38 .62
2.00 .00 .00 1.00 1.00 .00 .00 .36 .62
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(regression coefﬁcient 1.69, P ¼ .048).
ROC Curve Analysis
Considering failed mobilization, AUCs for day 1 CD34%
and CD34/mL were .93 (95% CI: .89 to .96) and .92 (95% CI: .87
to .95), respectively. Both were signiﬁcantly higher than .5
with P < .0001, whereas the difference (AUC1 e AUC2) was
not statistically signiﬁcant: .01 (95% CI: e.01 to .04, P ¼ .36).
For suboptimal mobilization, AUCs for day 1 CD34% and
CD34/mL were .93 (95% CI: .90 to .96) and .91 (95% CI: .86 to
.94), respectively, with a trend to a signiﬁcant difference: .02
(95% CI: e.004 to .05), P ¼ .09 (Figure 1A). Results were
similar when 44 second or third mobilization attempts were
excluded from the analysis (Figure 1B).
Considering that patients with day 1 CD34þ  20/mL
never failed mobilization, we limited ROC curve analysis to
138 of 280 procedures with a lower day 1 CD34þ count
(Figure 2A). In this setting, CD34% and CD34/mL AUCs for
failurewere .86 (95% CI: .78 to .91) and .81 (95% CI: .71 to .88),
respectively, with no signiﬁcant difference: .05 (95% CI: e.02
to .12), P¼ .15. For suboptimal mobilization, day 1 CD34% and
CD34/mL AUCwere .85 (95% CI: .77 to .90) and .78 (95% CI: .68
to .85), respectively; the difference (.07; 95% CI: .005 to .14)
was statistically signiﬁcant (P ¼ .03). Similar results were
obtained in 106 of 236 ﬁrst mobilization attempts with day 1
CD34þ < 20/mL (Figure 2B). The CD34% value with the best
cost-to-beneﬁt ratio was .07% (Table 3): in the complete
analysis of 280 mobilization attempts, This percentage
showed a sensitivity of 87%, a speciﬁcity of 65%, a positive
predictive value of 82%, and a negative predictive value ofFigure 2. ROC curves for mobilization procedures with day 1 CD34/mL < 20: al73%. Interestingly, with a CD34% cut-off of .5, the positive
predictive value was 100%, meaning all procedures with day
1 CD34%  .5 were successful. Under this value there was a
progressive reduction of the success rate: at a cut-off of .05%,
only 25% ofmobilizations were optimal. Considering patientsl mobilizations (n ¼ 138, A) and ﬁrst mobilization attempts (n ¼ 106, B).
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we performed a ROC curve analysis at day 2: in patients with
day 2 CD34þ < 20/mL, too, AUCs were .80 (95% CI: .67 to .89)
for CD34% and .77 (95% CI: .62 to .86) for CD34/mL (P for
difference .45). At day 2, a CD34% cut-off of .3 predicted 100%
optimal mobilizations (Table 3).
Algorithm for Early Identiﬁcation of Poor Mobilizers
We translated these results in the algorithm presented
in Figure 3. Brieﬂy, patients with CD34þ absolute counts
< 20/mL at hematological recovery but >.5% have a good
probability of mobilization continuing G-CSF alone; patients
with CD34þ < 20/mL and .5% have an intermediate risk of
failure and should be further evaluated at day 2. If CD34þ are
still less than 20/mL but greater than .3%, the probability of
failure is low, but if CD34% is lower than .3, PLX should be
used.
Validation Group
Between January and October 2013, 20 patients under-
went mobilization with chemotherapy followed by G-CSF.
Twelve patients with MM were treated with cyclophospha-
mide 3 to 4 g/m2 and performed their ﬁrst CD34 count on
day þ11; among 8 patients with lymphoma, 1 received
cyclophosphamide and 3 received DAOX (see Table 1 for
explanation of DAOX regimen), a schema similar to DHAP
(see Table 1 for explanation of DHAP regimen) with oxali-
platin 130 mg/m2 instead of cisplatin 100 mg/m2 on day 1
associated with dexamethasone 40 mg/d from days 1 to 4
and cytarabine 2 g/m2 every 12 hours on day 2. Four patients
were treated with other regimens (Table 1).Figure 3. Algorithm for on demand use of plerixaforMedian day 1 leukocyte count, CD34%, and CD34/mL were
5.1  109/L (range: 1.3 to 35), .68% (range: .02 to 4.17), and
42.5/mL (range: 2 to 274), respectively. Day 1 CD34/mL was
lower than 20 in 7 patients and lower than 5 in 5 patients; 6
of the 7 patients had CD34þ percentages less than .5% but
only in 2 was it less than .05%. On day 2 only 2 patients still
had CD34/mL lower than 20: 1 had CD34 percentage of 1.84%
and continued G-CSF alone, whereas the other had a per-
centage of .05% and received PLX. All mobilization pro-
cedures were successful with a median harvest of 11.2  106
CD34þ/kg (3.2 to 30.8).
DISCUSSION
Following the suggestion of To et al. [1] that individual
centers should analyze their own data to determine triggers
for immediate salvage PLX, we reviewed our experience of
the last 10 years to deﬁne early risk factors for mobilization
failure. Most of our MM patients were treated with cyclo-
phosphamide, whereas less than 30% of lymphoma patients
were treated with DHAP or cyclophosphamide. Globally,
failure rate was 12% and was higher in patients who had
already failed a mobilization attempt (23%) and in patients
with non-Hodgkin lymphoma treated with cyclophospha-
mide alone (23%) rather than cytarabine-based regimens.
CD34þ counts at hematological recovery signiﬁcantly
correlatedwith CD34þ harvest andwere less in patients who
failed harvest. Inmultivariate analysis, the impact of CD34/mL
and of CD34% was independent of both age and chemo-
therapy regimen, conﬁrming the well-known predictive
power of CD34/mL for collection CD34þ yield [19]. Interest-
ingly, the percent CD34þ value, rather than the absolute. WBC indicates total White Blood Cells count.
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outcome, with a higher regression coefﬁcient. The ROC curve
analysis conﬁrmed that in patients unsuitable to undergo
apheresis because of CD34þ values < 20/mL, the percent
CD34þ value was more reliable in predicting a successful
harvest in the following days than CD34/mL.
Blood samples from G-CSFemobilized patients contain
different cell populations: early CD34þ progenitor cells, other
mononuclear cells (lymphocytes and monocytes), gran-
ulocytes, band forms, and metamyelocytes [20]. Originally,
CD34þ absolute counts were generated in dual-platform
analysis multiplying the ﬂow cytometer percentage of
CD34þ by the leukocyte count generated from an automated
hematology analyzer. In 1998, the most widely used protocol
proposed by the International Society of Hematotherapy and
Graft Engineering was modiﬁed with the introduction of a
single-platform method, in which a known amount of ﬂuo-
rescentmicrobeads is mixedwith a stained blood sample and
absolute counts calculated as a ratio between beads and
CD34þ cells, thus reducing variability [21]. The ratio between
absolute CD34þ cells and leukocytes changes over time
during mobilizing treatment: in healthy volunteers given G-
CSF daily, the number of mobilized CD34þ peaked from day 4
to day 5 and slightly decreased on day 6, whereas leukocytes
increased from day 4 to day 6 [17]. We can postulate that
although patients with delayed leukocyte recovery show
initial low leukocyte and CD34þ absolute counts with a high
CD34þ percentage, poor-mobilizing patients do present low
CD34/mL counts but high total leukocytes counts, with low
CD34þ percentage. As a consequence, CD34þ absolute count
capability of predicting total harvest in apheresis performed
the same day is not to be questioned, but in patients with low
absolute CD34þ counts, the percent CD34 value could be a
better early predictor of stem cell harvest in the following
days. We therefore incorporated both indicators in our
algorithm.
Our data suggest that patients with day 1 CD34þ counts
lower than 20/mL but higher than .5% have a 100% probability
of optimal mobilization and should not receive PLX. Patients
with day 1 CD34þ counts lower than 20/mL and a percentage
less than .05% have a probability of failure higher than 50%.
However, if possible, we suggest waiting the day after: if on
day 2 CD34þ counts still are lower than 20/mL and also less
than .3%, chances of successful harvest with G-CSF alone are
very low.
PLX on demand is an effective strategy in poor-mobilizing
patients after chemotherapy and G-CSF [22-25]. D’Addio
et al. [24] described 13 MM and lymphoma patients who
were treated with PLX due to persistent peripheral blood
CD34þ counts lower than 10/mL and/or inadequate PBSC
collection, obtaining a 100% success rate. In a similar popu-
lation, Smith et al. [25] were able to collect more than 2 106
CD34þ/kg in 37 of 38 patients.
Several algorithms have been proposed to select patients
for early PLX addition to avoid both mobilization failure and
inappropriate administration of this expensive drug. Hay
et al. [16], moving from a retrospective analysis of 354
autologous apheresis attempts, proposed PLX administration
in patients with CD34/mL peak or plateau at 16.5/mL. In 107
patients treated with cyclophosphamide and G-CSF, Farina
et al. [14] showed that (1) delayed leukocyte recovery
(>12 days from administration of 3 to 4 g/m2 and >14 days
from administration of 6 to 7 g/m2) and (2) CD34þ less than
10/mL at leukocyte recovery signiﬁcantly increased the risk of
mobilization failure. They proposed an algorithm based onthese 2 independent variables, considering at high risk of
failure patients with both risk factors and at intermediate
risk patients with only 1 factor. Milone et al. [13] retrospec-
tively evaluated data on 233 patients treated with cyclo-
phosphamide 4 g/m2 and G-CSF and suggested that patients
with CD34þ less than 6/mL at day 12 or less than 10/mL at day
13 should be treated with PLX. This algorithm was validated
in a prospective study in which MM and lymphoma patients
notmobilizing up to 13 days from cyclophosphamide or up to
15 days from DHAP administration, respectively, received
PLX if the CD34þ count was lower than 10/mL. The PLX on
demand strategy signiﬁcantly reduced mobilization and
harvest failure in comparison with a “bias-adjusted set of
controls.”
Low- to intermediate-dose cyclophosphamide followed
by G-CSF is the most frequent chemomobilization strategy in
MM patients, whereas different regimens have been pro-
posed for lymphoma patients: DHAP, cyclophosphamide
alone, RICE (rituximab, ifosfamide, carboplatin, etoposide)
[26], high-dose cytarabine [27], high-dose methotrexate in
patients with central nervous system disease [28], and IGEV
(ifosfamide, gemcytabine, etoposide, vinorelbine) in patients
with relapsed or refractory Hodgkin lymphoma [29]. In these
cases, algorithms based on CD34þ count at a ﬁxed day after
starting chemotherapy are not applicable.
The proposed algorithm applicable to all patients, what-
ever the mobilizing schedule, was prospectively validated in
20 patients with good results: only 1 patient received PLX
and none failed mobilization. Interestingly, despite a very
low CD34þ absolute count on day 11 in some patients, both
algorithms proposed by Farina et al. [14] and by Milone et al.
[13] predicted a successful mobilization without PLX in pa-
tients mobilized with cyclophosphamide 3 to 4 g/m2. How-
ever, our algorithm was well predictive in lymphoma
patients in which the other algorithms could not be applied.
In conclusion, we showed a simple strategy for early
detection of poor-mobilizing patients based on peripheral
blood percentage of CD34þ at the ﬁrst and second days of
hematological recovery after chemotherapy plus G-CSF.
Given the retrospective nature of the analysis and the little
dimension of the prospective validation population, this
approach, as well as other algorithms for on-demand use of
PLX, should be evaluated in large prospective trials aiming to
deﬁne the most cost-effective strategy. Moreover, because
institutional practices vary, individual centers should deﬁne
their own speciﬁc cut-offs.ACKNOWLEDGMENTS
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